Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 21Recruiting 4Unknown 3Terminated 3Withdrawn 2Not yet recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 4Breast 3Tumor-Agnostic 2Genitourinary 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Prostatic Neoplasms 2

Interventions

pembrolizumab 65Nivolumab 58Magnetic Resonance Spectroscopy 53enzalutamide 39Abiraterone Acetate 37Radiosurgery 36Gemcitabine 35Specimen Handling 32Radiotherapy 32Ipilimumab 32Androgen Antagonists 32Prednisone 31apalutamide 28Cisplatin 28Docetaxel 27Leuprolide 26atezolizumab 25Carboplatin 25durvalumab 23cabozantinib 23darolutamide 20acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 19olaparib 18Goserelin 17Radiation 16Gonadotropin-Releasing Hormone 16Biopsy 16gallium 68 PSMA-11 15Pluvicto 15avelumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Therapeutics × Genitourinary × Clear all
NCT02023463 2025-11-25

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Thomas Jefferson University

Phase 1 Active not recruiting
25 enrolled
Genitourinary

Prostatic Neoplasms

NCT03531099 2025-06-22

HIFUSA

Hospices Civils de Lyon

Phase 3 Active not recruiting
108 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡